Phase 4
Completed N=72
Treatment of Zollinger-Ellison Syndrome With Prevacid
Zollinger-Ellison Syndrome · Multiple Endocrine Neoplasia
Source: ClinicalTrials.gov NCT00204373 ↗
Enrolled (actual)
72
Serious AEs
38.9%
Results posted
Oct 2012
Primary outcomePrimary: Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment. — 72 participants
Summary
The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment. |
72 | — |
| SECONDARY The Median Survival From the Time of Diagnosis. |
6.6 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed with Zollinger-Ellison syndrome
Exclusion Criteria
- Pregnant or lactating females
Data sourced from ClinicalTrials.gov (NCT00204373). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.